search

Active clinical trials for "Polycystic Kidney Diseases"

Results 41-50 of 165

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib...

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Subjects who received tesevatinib in Study KD019-101 and completed 24 months of treatment will continue on the dose of tesevatinib they were receiving at 24 months on the KD019-101 study.

Terminated3 enrollment criteria

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

Autosomal Dominant Polycystic KidneyADPKD

This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 850 patients will be enrolled.

Terminated23 enrollment criteria

A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney...

Autosomal Dominant Polycystic Kidney Disease

This is an exploratory, randomized, double-blind, placebo-controlled, parallel group, multicenter, proof of concept study (Phase 2a), evaluating orally administered GLPG2737 for a double-blind (DB) treatment period of 52 weeks and 4 weeks of follow up as well as an open-label extension (OLE) treatment period of 52 weeks and 4 weeks of follow-up, in subjects with rapidly progressing ADPKD.

Terminated17 enrollment criteria

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic...

Polycystic Kidney DiseaseAdult1 more

This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy of lixivaptan in participants who previously experienced liver chemistry test abnormalities while treated with tolvaptan and were permanently discontinued from the drug for that reason. Up to 50 eligible participants will be enrolled and treated with lixivaptan for 52 weeks following titration to an optimal dose.

Terminated34 enrollment criteria

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

Chronic Kidney DiseasesAlport Syndrome1 more

This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.

Terminated13 enrollment criteria

A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD...

Polycystic KidneyAutosomal Dominant

Primary Objective: To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage 1) and estimated glomerular filtration rate (eGFR) decline in participants at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Stage 2). Secondary Objectives: To determine the effect of venglustat on the rate of renal function decline (Stage 1) and on the rate of TKV growth (Stage 2). To evaluate the pharmacokinetics (PK) of venglustat in ADPKD participants (Stages 1 and 2). To determine the effect of venglustat on pain and fatigue, based on participant reported diary (Stages 1 and 2). Safety/tolerability objectives: To characterize the safety profile of venglustat (Stages 1 and 2). To evaluate the effect of venglustat on mood using Beck Depression Inventory II (BDI-II) (Stages 1 and 2). To evaluate the effect of venglustat on the lens by ophthalmological examination (Stages 1 and 2).

Terminated34 enrollment criteria

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat

Congenital Cystic Kidney Disease

Primary Objective: -To determine the effect of early versus delayed treatment with venglustat on the total kidney volume (TKV) in participants at risk of rapidly progressive autosomal dominant polycystic kidney disease (ADPKD). Secondary Objective: To determine the effect of early versus delayed treatment with venglustat on the renal function (estimated glomerular filtration rate [eGFR] [Chronic Kidney Disease Epidemiology Collaboration {CKD-EPI} equation]). To characterize the safety profile of venglustat. To evaluate the effect of venglustat on the lens by ophthalmological examination. To evaluate the effect of venglustat on mood using Beck Depression Inventory-II (BDI-II).

Terminated22 enrollment criteria

Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

The general aim of this study in adult patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and severe renal insufficiency is to assess the safety and the efficacy of sirolimus (SRL) in slowing renal function decline as compared to conventional therapy.

Terminated11 enrollment criteria

Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers...

Autosomal Dominant Polycystic Kidney Disease

Currently the only approved use for rapamycin (sirolimus) is for immunosuppression after renal transplantation. This trial is designed to determine whether rapamycin is safe and effective treatment for patients with polycystic kidney disease (ADPKD). Patients will be followed by volumetric magnetic resonance imaging (MRI) to observe for change in kidney (and cyst) size. Blood and urine samples will also be collected to evaluate for change in biomarkers with treatment.

Terminated13 enrollment criteria

Everolimus on CKD Progression in ADPKD Patients

Polycystic Kidney Diseases

The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down the progression of CKD in ADPKD patients.

Terminated10 enrollment criteria
1...456...17

Need Help? Contact our team!


We'll reach out to this number within 24 hrs